1. Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau HY, Lind S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988; 48:5883–5893.
2. Mitchell MS, Harel W, Kempf RA, Hu E, Kan-Mitchell J, Boswell WD, Dean G, Stevenson L. Activespecific immunotherapy for melanoma. J Clin Oncol 1990; 8:856–869.
3. Mitchell MS, Harel W, Kan-Mitchell J, LeMay LG, Goedegebuure P, Huang XQ, Hofman F, Groshen S. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action. Ann N Y Acad Sci 1993; 690:153–166.
4. Mitchell MS, Liggett PE, Green RL, Kan-Mitchell J, Murphree AL, Dean G, Spears L, Walonker F. Sustained regression of a primary choroidal melanoma under the influence of a therapeutic melanoma vaccine. J Clin Oncol 1994; 12:396–401.
5. Mitchell MS, Harel W, Groshen S. Association of HLA phenotype with response to active, specific immunotherapy of melanoma. J Clin Oncol 1992; 10:1158–1164.